Xcelience invests in CMO Powdersize

Xcelience invests in CMO Powdersize

Related tags Pharmacology

CDMO (contract development and manufacturing organization) Xcelience has made a structured cash investment in Pennsylvania-based Powdersize, which specializes in milling, micronization and powder size classification.  

The undisclosed investment will grow Powdersize’s business while simultaneously adding a complete set of particle size control solutions to Xcelience’s portfolio. Powdersize will also continue to expand its recently added facility to support the additional business expected with the integration and shared development projects. 

As we continue to build our suite of services, we are excited to join with Powdersize in an integration that combines their leadership and 23 years of milling and micronizing experience, with our two decades of expertise in drug development​,” said Derek Hennecke, President and CEO of Xcelience.  

Solubility has become a hot topic for pharma companies, especially as many drugs in current companies’ pipelines are poorly soluble. Reducing particle size through micronization is considered the leading technology for increasing the bioavailability of oral dosage forms when the API has solubility issues.  

This collaboration is a natural fit for both sides​,” says Wayne Sigler, CEO of Powdersize. “We fully expect both companies to benefit from each other’s strengths and capabilities in drug development and commercial products​.”  

Investment bank Fairmount Partners provided financial advisory services supporting the owners of Powdersize.  

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more